Albireo Pharma (Albireo Pharma) Total Assets : $321.22 Mil (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Total Assets?

Albireo Pharma's Total Assets for the quarter that ended in Sep. 2022 was $321.22 Mil.

During the past 12 months, Albireo Pharma's average Total Assets Growth Rate was 191.90% per year. During the past 3 years, the average Total Assets Growth Rate was 35.70% per year. During the past 5 years, the average Total Assets Growth Rate was 138.60% per year. During the past 10 years, the average Total Assets Growth Rate was 51.40% per year.

During the past 13 years, Albireo Pharma's highest 3-Year average Total Assets Growth Rate was 464.20%. The lowest was -48.70%. And the median was 16.95%.

Total Assets is connected with ROA %. Albireo Pharma's annualized ROA % for the quarter that ended in Sep. 2022 was -54.96%. Total Assets is also linked to Revenue through Asset Turnover. Albireo Pharma's Asset Turnover for the quarter that ended in Sep. 2022 was 0.04.

Albireo Pharma Total Assets Historical Data

The historical data trend for Albireo Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Total Assets Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Assets

Get a 7-Day Free Trial

73.22

185.47

165.07

285.61

302.05

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Assets	Get a 7-Day Free Trial															296.45	302.05	261.26	229.01	321.22

Albireo Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Albireo Pharma's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	175.608	+	126.443
	=	302.05

Albireo Pharma's Total Assets for the quarter that ended in Sep. 2022 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2022 )	+	Total Liabilities (Q: Sep. 2022 )
	=	100.071	+	221.151
	=	321.22

Albireo Pharma (NAS:ALBO) Total Assets Explanation

Total Assets is connected with ROA %.

Albireo Pharma's annualized ROA % for the quarter that ended in Sep. 2022 is

ROA %	=	Net Income (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
	=	-151.2	/	( (229.014	+	321.222)	/ 2 )
	=	-151.2	/	275.118
	=	-54.96 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Albireo Pharma's Asset Turnover for the quarter that ended in Sep. 2022 is

	Asset Turnover
=	Revenue (Q: Sep. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
=	9.832	/	( (229.014	+	321.222)	/ 2 )
=	9.832	/	275.118
=	0.04

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Albireo Pharma Total Assets Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (Albireo Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Executives

Harford Simon N.r.	officer: CFO and Treasurer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson	officer: Chief Commercial Officer	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter	officer: Chief Regulatory Officer	C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson	officer: Chief Operating Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham	officer: Chief Human Resources Officer	10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan	officer: General Counsel	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson	director	852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina	director	C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn	officer: Chief Medical Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003